Dr. Divyank Pathak

Comprehensive pediatric care focused on early diagnosis, timely intervention, and long-term child wellness is offered by Dr. Divyank Pathak, who emphasizes preventive healthcare through regular growth monitoring, immunizations, nutritional guidance, and parental counselling. With a family-centred approach, he ensures every child receives personalized care that supports healthy development from infancy through adolescence.

Dr. Divyank Pathak specializes in managing complex and treatment-resistant asthma in children with a structured, evidence-based approach. He focuses on detailed trigger evaluation, optimization of inhaled therapies, and personalized long-term control plans. His goal is to reduce hospitalizations, prevent flare-ups, and help children achieve sustained asthma control and better quality of life.

Comprehensive evaluation and advanced management of pediatric allergies and asthma are provided by Dr. Divyank Pathak, focusing on accurate diagnosis and long-term disease control. He specializes in allergy testing, asthma phenotyping, and individualized treatment plans tailored to each child’s needs. With an emphasis on prevention, education, and lifestyle modification, he helps children achieve better symptom control and an improved quality of life.

Dr. Divyank Pathak provides comprehensive allergy evaluation to identify triggers contributing to asthma and recurrent respiratory symptoms in children. He emphasizes preventive strategies, environmental control measures, and early intervention to limit disease progression. His evidence-based approach helps reduce flare-ups and supports long-term respiratory health.

Dr. Divyank Pathak explains that sepsis is a life-threatening response to infection, where the body’s immune system overreacts, causing widespread inflammation and tissue damage. If not treated promptly, it can progress to multi-organ dysfunction syndrome (MODS), leading to failure of two or more organs. Early recognition, timely antibiotics, and comprehensive supportive care are critical to improving survival.

Childhood asthma is the most common chronic respiratory condition in children and remains significantly under-diagnosed in Varanasi and across Eastern Uttar Pradesh, where persistent cough is frequently attributed to recurrent infection rather than allergic airway inflammation. Dr Divyank Pathak provides expert diagnosis and long-term management of childhood asthma at Vatsalya Superspeciality Children Hospital, Varanasi, using clinical assessment, spirometry, skin prick allergy testing, and structured stepped treatment protocols. As the Director of one of Uttar Pradesh's few dedicated paediatric allergy and asthma centres, with Diploma in Paediatric Allergy and Asthma from Sir Ganga Ram Hospital in association with the University of Colorado, he evaluates each child's allergen sensitisation profile, asthma phenotype, and current treatment adequacy to build a personalised long-term management plan focused on sustained symptom control. Written by Dr Divyank Pathak, MBBS, MD (Pediatrics), IFPCCM, DPAA, FNPP, DPSM, FAAP, Director and Senior Consultant Paediatrician, Pediatric Critical Care and Allergy and Asthma Specialist, Vatsalya Superspeciality Children Hospital, Mahavir Road, Varanasi, Uttar Pradesh 221002.

Difficult-to-treat asthma in children is defined as persistent symptoms despite appropriate controller therapy at adequate doses with confirmed good inhaler technique, and requires systematic specialist evaluation to distinguish true severe asthma from asthma made difficult by modifiable factors such as poor inhaler technique, allergen exposure, untreated rhinitis, or non-adherence. Dr Divyank Pathak provides structured evaluation and management of difficult-to-treat and severe asthma in children at Vatsalya Superspeciality Children Hospital, Varanasi. His assessment protocol addresses all modifiable barriers to asthma control before any decision to escalate treatment is made. For children with confirmed severe asthma where standard treatment is insufficient, advanced therapeutic options including biological agents targeting specific inflammatory pathways are discussed where clinically appropriate. His IFPCCM fellowship and paediatric critical care expertise mean he is equipped to manage children whose severe asthma leads to life-threatening exacerbations requiring intensive care support. Written by Dr Divyank Pathak, MBBS, MD (Pediatrics), IFPCCM, DPAA, FNPP, DPSM, FAAP, Director and Senior Consultant Paediatrician, Pediatric Critical Care and Allergy and Asthma Specialist, Vatsalya Superspeciality Children Hospital, Mahavir Road, Varanasi, Uttar Pradesh 221002.

Every treatment prescribed for a child with asthma - the daily preventer inhaler, the antihistamine for rhinitis, the emollient for eczema - manages the symptoms that allergic immune dysregulation produces. None of them change the immune dysregulation itself. Allergen immunotherapy is the single exception: the only treatment that modifies the underlying allergic mechanism, training the immune system to tolerate the allergen rather than reacting to it, and producing clinical benefits that persist for years after the treatment course ends. Dr. Divyank Pathak's DPAA - Diploma in Paediatric Allergy and Asthma - provides the specialist allergy and immunotherapy training that his practice at Vatsalya Superspeciality Children Hospital, Varanasi, is built around. Allergen immunotherapy is offered for children who have: confirmed IgE-mediated allergic sensitisation through skin prick testing or specific IgE blood testing; symptoms of allergic rhinitis, asthma, or both that significantly affect quality of life, school attendance, or sleep; and inadequate disease control despite appropriate pharmacotherapy and allergen avoidance. The allergen causing the disease must be one for which effective immunotherapy preparations are available - house dust mite, cockroach, and local pollens are the most clinically relevant sensitisations in the Varanasi and Eastern UP context. Both subcutaneous immunotherapy (SCIT, administered as injections in clinic) and sublingual immunotherapy (SLIT, taken as daily drops at home) are available, with the choice between routes based on the child's age, the allergen, the family's capacity for clinic attendance, and the clinical characteristics of the child's disease. The treatment course is three to five years. Benefits - reduced rhinitis symptoms, improved asthma control, reduced medication requirement, and in children, evidence that immunotherapy may slow the progression of allergic rhinitis to asthma - become apparent within the first six to twelve months and deepen over the full treatment course.

Subcutaneous allergen immunotherapy - SCIT - is the injection-route form of allergen immunotherapy and the most extensively studied form of disease-modifying allergy treatment available. It is administered as injections into the subcutaneous tissue of the upper arm, using allergen extracts standardised to the specific sensitisations identified on allergy testing, in gradually increasing doses during a build-up phase followed by a regular maintenance dose. The mechanism is the same as sublingual immunotherapy: progressive exposure to the allergen at doses that induce immune tolerance rather than immune reactivity, shifting the immune response from the allergic Th2-dominant pattern toward a tolerant Th1 and regulatory T-cell pattern. The clinical result - reduced allergic reactivity, fewer rhinitis and asthma symptoms, lower medication requirements - is durable and persists for years after the treatment course ends. Dr. Divyank Pathak administers SCIT at Vatsalya Superspeciality Children Hospital, Varanasi, for children with confirmed allergen sensitisation - house dust mite, cockroach, and relevant local pollens from the Eastern UP environment - who meet the criteria for immunotherapy. The build-up phase involves clinic visits, typically weekly or fortnightly, during which the allergen dose is gradually increased to the maintenance level. After maintenance is reached, injections are administered monthly. The full course is three to five years. SCIT requires the child to remain in the clinic for 20 to 30 minutes after each injection for observation - a requirement that is the principal difference from SLIT, which is taken at home. For families in Varanasi who can attend regularly, SCIT is the treatment with the longest evidence base and the most rigorous clinical trial data for efficacy in allergic rhinitis and asthma.